← Back to patent-cliff list
Amikacin liposomal (Insmed)
Tier C — Watch / tradeAmikacin liposomal (Insmed)
Transave Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：30S subunit
Brand：ARIKAYCE, Arikace, Arikayce, Arikayce Kit
Indications (approved)：Respiratory tract infection
Regional status
US
-
EU
Approved
2020-10-27
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Amikacin liposomal (Insmed)?
Approved indications include: Respiratory tract infection.
When does the Amikacin liposomal (Insmed) patent expire?
No public expiry year is available for Amikacin liposomal (Insmed) yet; this page updates once verified.
How do I get a quote for Amikacin liposomal (Insmed) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27